XOMA
XOMA Royalty CorpPrice
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Jul 14. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q3 2026: 0 added (0 new), 6 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate $0.228 → $0.500 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +1.8% to 914.9K shares. 5.0 days to cover, ≈7.3% of shares.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | EXIT | $0.00 |
| BlackRock, Inc. | EXIT | $0.00 |
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | $0.00 |
| FMR LLC | EXIT | $0.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | EXIT | $0.00 |
| Woodline Partners LP | ADD | $47.4M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $7.5M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | $3.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Apr 2026| Date | Firm | Rating |
|---|---|---|
| Apr 30, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Mar 20, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Feb 24, 2026 | Leerink Partners MAINTAIN | Outperform |
| Dec 11, 2025 | HC Wainwright & Co. MAINTAIN | Buy |
| Dec 11, 2025 | Leerink Partners MAINTAIN | Outperform |
| Dec 9, 2025 | LUCID CAPITAL MARKETS INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Montano Maricel Perea Chief Legal Officer Jul 14, 2026 | OTHER | 65 sh |
Montano Maricel Perea Chief Legal Officer Jul 14, 2026 | TO ISSUER | 37,074 sh |
Montano Maricel Perea Chief Legal Officer Jul 14, 2026 | TO ISSUER | 11,316 sh |
LIMBER JOSEPH M Director Jul 14, 2026 | OTHER | 9,532 sh |
LIMBER JOSEPH M Director Jul 14, 2026 | TO ISSUER | 10,000 sh |
LIMBER JOSEPH M Director Jul 14, 2026 | TO ISSUER | 20,000 sh |
LIMBER JOSEPH M Director Jul 14, 2026 | TO ISSUER | 8,000 sh |
LIMBER JOSEPH M Director Jul 14, 2026 | TO ISSUER | 2,366 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current FY | $0.55 | $0.55–$0.55 | +266.7% | $65.0M |
| Next FY | None | None | No data | $0.00 |
| Current Q | $0.50 | $0.50–$0.50 | +185.7% | $16.1M |
| Next Q | $0.52 | $0.52–$0.52 | +100.0% | $16.4M |
Short side
FINRA· Jun 30, 2026| Jul 13, 2026 | Deletion | Resumed |
SecBot reports
5 filings · 3 press releases · 2 bullish · 1 bearish · 2 neutral- BEARISH 15-12GJul 27, 2026
XOMA Royalty Corp filed a Form 15-12G to terminate its SEC registration under Section 12(g)…
XOMA has effectively gone dark with only one holder of record, likely following a going-private transaction. Traders should expect the stock to be delisted from Nasdaq and move to OTC or cease…
- BULLISH 8-KJul 14, 2026
XOMA Royalty Corp. completed its acquisition by Ligand Pharmaceuticals on July 14, 2026. Common…
The acquisition has closed; XOMA common and preferred shares are no longer trading. For common holders, the only remaining value is the $39.00 cash per share already received and the CVR tied to…
- BULLISH DEFA14AJun 12, 2026
XOMA Royalty Corp filed additional definitive proxy soliciting materials (DEFA14A) confirming its…
The merger with Ligand is firmly on track with a specific closing date of July 14, 2026. Common shareholders should be aware of the CVR record date and mechanics. Preferred shareholders should…
- NEUTRAL 8-KJun 12, 2026
XOMA Royalty Corp announced that the previously announced acquisition by Ligand Pharmaceuticals is…
For common stock holders, the merger timeline solidification and preferred redemption remove overhang and simplify the capital structure ahead of the acquisition. Monitor the stockholder vote and…
All XOMA filing & press-release reports (8)
- 15-12G reportJul 27, 2026
- 8-K reportJul 14, 2026
- DEFA14A reportJun 12, 2026
- 8-K reportJun 12, 2026
- PRESS-RELEASE reportMar 18, 2026
- 8-K reportMar 18, 2026
- PRESS-RELEASE reportMar 18, 2026
- PRESS-RELEASE reportMar 12, 2026